AGMB
AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ · Healthcare · Biotechnology · BE
$15.78
+6.41%Income statement
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | — | — | — | — |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Operating Expenses | ||||
| R&D Expense | 48.9M | 39.3M | 26.3M | 19.4M |
| SG&A Expense | 12.6M | 9.8M | 6.0M | 4.5M |
| General & Admin Expense | 12.6M | 9.8M | 6.0M | 4.5M |
| Selling & Marketing Expense | — | — | — | — |
| Other Expenses | (2.2M) | (1.1M) | (1.1M) | (1.3M) |
| Total Operating Expenses | 59.3M | 48.0M | 31.2M | 22.6M |
| Cost and Expenses | 59.3M | 48.0M | 31.2M | 22.6M |
| Operating Income (EBIT) | (59.3M) | (48.0M) | (31.2M) | (22.6M) |
| Non-Operating | ||||
| Interest Income | 1.6M | 1.2M | 245.0K | 71.0K |
| Interest Expense | 60.0K | 67.0K | 31.0K | 45.0K |
| Net Interest Income | 1.5M | 1.2M | 214.0K | 26.0K |
| Other Non-Op Income/Expense | (3.3M) | 1.8M | 19.2M | 11.8M |
| Non-Operating Income (excl Interest) | 3.2M | (1.8M) | (19.2M) | (11.9M) |
| EBT (Pre-Tax Income) | (62.5M) | (46.3M) | (12.0M) | (10.8M) |
| Income Tax Expense | — | 4.0K | (619.0K) | (2.7M) |
| Bottom Line | ||||
| Net Income | (62.5M) | (46.3M) | (11.4M) | (8.1M) |
| Earnings from Cont. Ops | (62.5M) | (46.3M) | (11.4M) | (8.1M) |
| Earnings from Discont. Ops | — | — | — | — |
| Bottom Line Net Income | (62.5M) | (46.3M) | (11.4M) | (8.1M) |
| Per Share | ||||
| Basic EPS | ($1.28) | ($1.26) | ($0.31) | ($0.22) |
| Diluted EPS | ($1.28) | ($1.26) | ($0.31) | ($0.22) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | ||||
| Basic Shares Outstanding | 48.7M | 36.2M | 36.2M | 36.2M |
| Diluted Shares Outstanding | 48.7M | 36.2M | 36.2M | 36.2M |
| Profitability Metrics | ||||
| EBITDA | (62.3M) | (45.9M) | (11.9M) | (10.7M) |
| D&A | 219.0K | 311.0K | 99.0K | 23.0K |
| EBIT | (62.5M) | (46.2M) | (12.0M) | (10.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025